MIDA boronate allylation – synthesis of ibuprofen by Phillips, David et al.
RSC Advances
PAPER
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
A
ug
us
t 2
02
0.
 D
ow
nl
oa
de
d 
on
 8
/2
0/
20
20
 2
:4
8:
01
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View IssueMIDA boronate aSchool of Chemistry, University of Glasgow
france@glasgow.ac.uk
† Electronic supplementary informa
10.1039/d0ra03338c
Cite this: RSC Adv., 2020, 10, 30624
Received 14th April 2020
Accepted 25th July 2020
DOI: 10.1039/d0ra03338c
rsc.li/rsc-advances
30624 | RSC Adv., 2020, 10, 30624llylation – synthesis of ibuprofen†
David Phillips, Glen Brodie, Sarah Memarzadeh, Gi Lum Tang and David J. France *
MIDA boronates are among the most useful reagents for the Suzuki–Miyaura reaction. This chemistry
typically generates new bonds between two aromatic rings, thereby restricting access to important areas
of chemical space. Here we demonstrate the coupling of MIDA boronates to allylic electrophiles,
including a new synthesis of the well-known COX inhibitor ibuprofen.Introduction
N-Methyliminodiacetic acid (MIDA) boronates are one of the
most useful organoboranes for the Suzuki–Miyaura cross-
coupling strategy, as pioneered by Burke et al. (Fig. 1).1 In
addition to helping to suppress undesired side reactions such
as protodeboronation, these BMIDA compounds have shown
promise in enabling carbon–carbon bond formation through an
iterative “building block” approach. This chemistry takes
advantage to two key properties of MIDA boronates to enable
iterative couplings: the orthogonal reactivity of these boronates
under aqueous vs. anhydrous conditions, and crucially a “catch-
and-release” purication based on the chromatographic prop-
erties of the BMIDA functionality. By deprotecting MIDA boro-
nates under aqueous conditions, followed by Pd-catalyzed
coupling, a wide array of targets have been prepared using this
methodology including natural products, pharmaceuticals,
biological probes, and materials components.2 Related work by
Watson et al. has used a controlled speciation approach for
iterative biaryl coupling of boronic acid pinacol esters with
MIDA boronates.3 While iterative strategies are widely used for
generating biopolymers like polypeptides and polynucleic
acids, the diversity of chemical bonds found in small molecules
has hindered the development of an approach to preparing
these compounds that is both modular and general. Iterative
synthesis strategies that can address the challenging structural
complexity posed by small molecules thus have the potential to
transform the way synthetic chemistry is conducted.4
Use of MIDA boronates in Pd-catalyzed coupling has enabled
the synthesis of a wide array of targets.2,4 A hallmark of these Pd-
catalyzed C–C bond formations is that they are used almost
universally to couple two carbons that are sp2 hybridised, most
commonly 2 aromatic rings. The relative ease with which at
aromatic rings can be coupled has contributed to the, Glasgow, G12 8QQ, UK. E-mail: david.
tion (ESI) available. See DOI:
–30630proliferation of these structures in MedChem programmes,
however it is now deemed partially responsible for the current
crisis in compound attrition rate.5 This drawback is also
important because increased sp3-C content correlates to clinical
success.6 Very few examples of coupling MIDA boronates to sp3
hybridised carbons are to be found in the literature,7 and we
chose to further explore this chemistry (Fig. 1b), including in
the context of drug synthesis. Our approach builds upon the
well precedented allylation of boronic acids,8 while enabling the
synthesis of new targets that could not be accessed using
standard Csp2–Csp2 MIDA boronate coupling chemistry (Fig. 2).Results and discussion
Our initial efforts to allylate aryl BMIDA compounds were
quickly rewarded, as 2-naphthyl MIDA boronate could beFig. 1 (a) Previous BMIDA coupling strategies (b) proposed BMIDA
allylation to expand scope to generating new bonds to sp3-hybridized
carbons.
This journal is © The Royal Society of Chemistry 2020
Fig. 2 Potential bioactive targets for a MIDA boronate allylation
approach to C–C coupling.9
Fig. 4 Substrate scope of allyl halide partner. aMajor regioisomer
shown.
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View Article Onlineefficiently coupled with allyl bromide using standard hydrolysis
conditions (Fig. 3). Pleasingly, the reaction could be extended to
aryl halide containing substrates functionalized at each posi-
tion of a phenyl ring. Clearly these functional handles allow for
further couplings. Furthermore, electron withdrawing nitro and
cyano substituents were well tolerated, and a vinyl MIDA boro-
nate could also be coupled. Use of an unprotected phenol
resulted in a decreased yield of the desired product of C–C bond
formation, due in large part to competing O-allylation, even
when K3PO4 was replaced with the milder base NaHCO3. 2-Fig. 3 Substrate scope of BMIDA precursor with allyl bromide and
cinnamyl chloride. Yields reported are by NMR unless stated. aK3PO4
replaced with NaHCO3.
bReaction carried out at room temperature.
cDioxane replaced with benzene. dIsolated yield.
This journal is © The Royal Society of Chemistry 2020MIDA boronate substituted furan and N-Boc-pyrrole could also
be allylated in moderate yield. Attempted allylation of other
heterocycles including 3-pyridyl MIDA boronate was less
successful, due in part to competing side reactions such as N-
allylation. Interestingly, we were able to couple neo-pentyl
BMIDA to cinnamyl chloride resulting in a new sp3–sp3 C–C
bond (9l). This process did not prove general, with other sp3–sp3
candidates such as methyl BMIDA and cyclobutyl BMIDA
having limited success (data not shown). Finally, we were able to
couple a BMIDA-modied phenylalanine to cinnamyl chloride
in excellent yield, demonstrating this methodology's potential
use in peptide modication.
Next, we chose to examine the substrate tolerance on the allyl
halide component by coupling 2-naphthyl MIDA boronate 7a
with a range of commercial allyl halides (Fig. 4). 2-Methyl allyl
bromide reacted successfully in comparable yield to the
unfunctionalized system above. Coupling of cinnamyl chloride
also proceeded well, and with excellent regiocontrol. BMIDA
allylation with 1-methyallyl chloride and prenyl chloride resul-
ted in decreased regioselectivity, though still good isolated
yields.
In order to study the mechanism of the BMIDA allylation, we
undertook a deuterium labelling study using dideuterioallyl
bromide (Fig. 5). Coupling with 2-naphthyl MIDA boronate
proceeded well, providing deuterated products 13 and 14 in
83% combined yield, but more importantly in a 1 : 1 ratio. This
outcome is consistent with the intermediacy of p-allyl speciesFig. 5 Isotopically labelled mechanistic probe.
RSC Adv., 2020, 10, 30624–30630 | 30625
Fig. 6 Synthesis of ibuprofen using BMIDA allylation.
RSC Advances Paper
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View Article Online12, formed by oxidative addition to the allyl halide, and trans-
metallation with the boronic acid generated in situ.
Finally, we chose to exemplify the utility of the BMIDA ally-
lation methodology by featuring it in the synthesis of the well-
known NSAID ibuprofen (Fig. 6). Our initial approach called
for an enolate arylation reaction of a propionate ester with p-
bromo aryl BMIDA 4.10 Several conditions proved unsuccessful,
likely due to complications arising from the MIDA functional
group. Recourse to a Negishi arylation11 of a-bromo-t-butyl
propionate however proved successful using QPhos as a ligand
for Pd.12 Pleasingly, BMIDA allylation of 16 proceeded well,
providing the coupled product in 73% isolated yield. Comple-
tion of the synthesis of ibuprofen was realized by alkene
hydrogenation and deprotection of the carboxylic acid.
Attempts to use the same Pd source to effect multiple trans-
formations in this synthesis met with limited success.Conclusions
We have expanded the scope of MIDA boronate coupling to
generate new bonds to sp3-hybridized carbons directly. The
coupling is tolerant of a range of functional groups, including
aryl halides, can be used with different allyl halide electro-
philes, and is competent for sp3–sp3 C–C bond formation. This
transformation can serve as a useful addition to the BMIDA-
based approach to generating small molecules, as shown by
a new synthesis of the widely used drug ibuprofen.Experimental section
Reactions involving air-sensitive agents and dry solvents were
performed in glassware that had been dried in an oven (150 C)
or ame-dried prior to use. These reactions were carried out
with the exclusion of air using an argon atmosphere. NMR
spectra were recorded on a Bruker DPX-400 spectrometer (1H
NMR at 400MHz and 13C NMR at 100MHz) or a Bruker DPX-500
spectrometer (1H NMR at 500 MHz and 13C NMR at 125 MHz).30626 | RSC Adv., 2020, 10, 30624–30630Chemical shis are reported in ppm. 1H NMR spectra were
recorded with CDCl3 or d6-DMSO as the solvent using residual
proton-containing solvent as internal standard, and for 13C
NMR spectra the chemical shis are reported relative to the
central resonance of CDCl3 or d6-DMSO. Signals in NMR spectra
are described as singlet (s), doublet (d), triplet (t), multiplet (m),
etc. or combination of these, which refers to the spin–spin
coupling pattern observed. Spin–spin coupling constants re-
ported are uncorrected. Two-dimensional (COSY, HSQC,
HMBC, NOESY) NMR spectroscopy was used where appropriate
to assist the assignment of signals in the 1H and 13C NMR
spectra. IR spectra were obtained employing a Shimadzu FTIR-
8400 instrument with a Golden Gate™ attachment that uses
a type IIa diamond as a single reection element so that the IR
spectrum of the compound (solid or liquid) could be detected
directly (thin layer). High resolution mass spectra were recorded
under FAB, ESI, EI and CI conditions by the analytical services at
the University of Glasgow. Flash column chromatography was
performed using forced ow of the indicated solvent system on
EMD Geduran Silica Gel 60 as solid support and HPLC graded
solvents as eluant. Reactions were monitored by thin layer
chromatography (TLC) on Merck silica gel 60 covered
aluminium sheets. TLC plates were developed under UV-light
and/or with an acidic ethanolic anisaldehyde solution or
a KMnO4-solution. All reagents were purchased from commer-
cial suppliers and used without further purication unless
otherwise stated.
2-Naphthyl boronic acid MIDA ester (7a)
Following a literature procedure,13 naphthyl boronic acid
(0.86 g, 5.0 mmol) and MIDA (0.74 g, 5.0 mmol) were stirred in
DMF (15 mL) at 85 C for 16 h then allowed to cool to room
temperature. The reaction mixture was diluted with EtOAc (100
mL) and H2O (100 mL) then separated. The organic phase was
washed with H2O (50 mL) and brine (3  50 mL) then dried
(Na2SO4), ltered and concentrated in vacuo. Purication by
ash chromatography (diethyl ether : methanol, 98.5 : 1.5 then
THF) gave a yellow oil. Addition of Et2O formed a white
precipitate which was collected by vacuum ltration affording
the title compound as a white solid (1.3 g, 93%). Analytical data
were in accordance with literature values.13 1H NMR (400 MHz,
d6-DMSO) d (ppm): 7.99 (1H, s, Ar-H), 7.94–7.88 (3H, m, Ar-H),
7.57–7.50 (3H, m, Ar-H), 4.38 (2H, d, J ¼ 17.2 Hz, 2 NCHH),
4.17 (2H, d, J ¼ 17.1 Hz, 2 NCHH), 2.52 (3H, s, NCH3).
Neopentyl boronic acid MIDA ester (7l)
Neopentyl boronic acid (200mg, 1.72mmol) andMIDA (253mg,
1.72 mmol) were stirred in DMF (5 mL) at 85 C for 16 h then
allowed to cool to room temperature. The reaction mixture was
diluted with EtOAc (30 mL) and H2O (30 mL) then separated.
The organic phase was washed 3 times with 5% LiCl solution
then dried over Na2SO4, ltered and concentrated in vacuo. The
residue was dissolved in a minimal amount of MeCN and
dropped into ice-cold Et2O forming a white precipitate. The
solvent was removed by ltration affording the title compound
as a white solid (226mg, 58%). 1H NMR (400MHz, CDCl3) d 3.76This journal is © The Royal Society of Chemistry 2020
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View Article Online(d, J ¼ 16.2 Hz, 2H, NCHH), 3.60 (d, J ¼ 16.1 Hz, 2H, NCHH),
2.84 (s, 3H, NCH3), 1.04 (s, 9H, 3 CH3), 0.58 (s, 2H, CH2); 13C
NMR (100 MHz, CDCl3) d 166.9 (2 C), 110.1 (CH2), 61.4 (2
CH2), 45.5 (CH3), 32.4 (3 CH3), 30.3 (C); IR (solid) 2949, 2862,
1739, 1464, 1109, 1032 cm1; HRMS (ESI) exact mass calculated
for C10H18NO4
10BNa [M + Na]+ m/z 249.1257, found m/z
249.1248.(S)-(4-(2-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)
phenyl)boronic acid MIDA ester (7m)
The boronic acid (200 mg, 0.620 mmol) and MIDA (91 mg, 0.62
mmol) were stirred in DMF (5 mL) at 85 C for 16 h then allowed
to cool to room temperature. The reaction mixture was diluted
with EtOAc (30 mL) and H2O (30 mL) then separated. The
organic phase was washed 3 times with 5% LiCl solution then
dried over Na2SO4, ltered and concentrated in vacuo. The
residue was dissolved in a minimal amount of MeCN and
dropped into ice-cold Et2O forming a white precipitate. The
solvent was removed by ltration affording the title compound
as a white solid (223 mg, 82%).1H NMR (400 MHz, CDCl3) d 7.45
(d, J ¼ 7.8 Hz, 2H, Ar-H), 7.16 (d, J ¼ 7.9 Hz, 2H, Ar-H), 5.00 (d, J
¼ 8.1 Hz, 1H, NH), 4.62–4.52 (m, 1H, CH), 3.95 (d, J ¼ 16.4 Hz,
2H, NCHH), 3.76 (dd, J ¼ 16.4, 4.7 Hz, 2H, NCHH), 3.71 (s, 3H,
OCH3), 3.13 (dd, J ¼ 13.4, 5.4 Hz, 1H, CHH), 3.03 (dd, J ¼ 13.4,
6.3 Hz, 1H, CHH), 2.54 (s, 3H, NCH3), 1.41 (s, 9H, 3 CH3); 13C
NMR (100MHz, CDCl3) d 172.3 (C), 167.8 (2 C), 155.2 (C), 138.2
(C), 132.6 (2 CH), 129.5 (2 CH), 80.1 (C), 61.9 (2 CH2), 54.6
(CH), 52.4 (CH3), 47.7 (CH3), 38.5 (CH2), 28.4 (3 CH3). The 13C
peak corresponding to the carbon atom adjacent to the boron
atom was not observed. IR (thin lm) 2980, 1743, 1705, 1612,
1500, 908 cm1; HRMS (ESI) exact mass calculated for C20H27-
N2O8
10BNa [M + Na]+ m/z 457.1753, found m/z 457.1751.General procedure for allylation of MIDA boronates
A screw-top glass vial was charged with boronic acid MIDA ester
(1 equiv.), dioxane (0.08M), allyl bromide (2 equiv.) and Pd2dba3
(5 mol%). A 3 M aq. solution of K3PO4 (1 : 5 v/v ratio to dioxane)
was added and the vial sealed under ambient atmosphere. The
resulting mixture was heated to 60 C by immersion of the
entire vial into a preheated aluminium block until the substrate
had been consumed, as judged by TLC analysis. The reaction
mixture was cooled to room temperature, quenched with 1 M
aq. NaOH then extracted with Et2O (3). The combined organic
extracts were dried (Na2SO4), ltered and concentrated in vacuo.
Addition of 1,3,5-trimethoxybenzene (17 mg, 0.10 mmol)
allowed determination of the yield by 1H NMR.
2-Allylnaphthalene (9a). The general procedure was
employed for the allylation of 2-naphthylboronic acid MIDA
ester (28 mg, 0.10 mmol). Yield determined by 1H NMR: 91%.
Analytical data were in accordance with literature values.14 1H
NMR (400 MHz, CDCl3) d 7.86–7.81 (3H, m, Ar-H), 7.67 (1H, s,
Ar-H), 7.51–7.44 (2H, m, Ar-H), 7.37 (1H, dd, J ¼ 8.4, 1.8 Hz, Ar-
H), 6.10 (1H, ddt, J¼ 16.8, 10.1, 6.7 Hz, CH]CH2), 5.19 (1H, dq,
J ¼ 10.5, 1.7 Hz, C]CHa), 5.17–5.15 (1H, m, C]CHb), 3.59 (2H,
d, J ¼ 6.6 Hz, CH2).This journal is © The Royal Society of Chemistry 20202-Allyluorobenzene (9b). The general procedure was
employed for the allylation of 2-uorophenylboronic acid MIDA
ester (25 mg, 0.10 mmol). Yield determined by 1H NMR: 83%.
Analytical data were in accordance with a commercial sample.
1H NMR (400 MHz, CDCl3) d 7.22–7.16 (2H, m, Ar-H), 7.09–6.98
(2H, m, Ar-H), 6.01–5.91 (1H, m, CH]CH2), 5.10–5.05 (2H, m,
CH]CH2), 3.41 (2H, dd, J ¼ 6.6, 1.5 Hz, CH2).
4-Allylchlorobenzene (9c). The general procedure was
employed for the allylation of 4-chlorophenylboronic acid MIDA
ester (27 mg, 0.10 mmol). Yield determined by 1H NMR: 92%.
Analytical data were in accordance with literature values.15 1H
NMR (400 MHz, CDCl3) d 7.29–7.25 (2H, m, Ar-H), 7.14–7.11
(2H, m, Ar-H), 5.94 (1H, ddt, J ¼ 17.2, 10.4, 6.8 Hz, CH]CH2),
5.11–5.10 (1H, m, CH]CHa), 5.09–5.05 (1H, m, CH]CHb), 3.36
(2H, d, J ¼ 6.7 Hz, CH2).
4-Allylbromobenzene (9d). The general procedure was
employed for the allylation of 4-bromophenylboronic acid
MIDA ester (31 mg, 0.10 mmol). Yield determined by 1H NMR:
90%. Analytical data were in accordance with literature values.15
1H NMR (400 MHz, CDCl3) d 7.45–7.39 (2H, m, Ar-H), 7.09–7.04
(2H, m, Ar-H), 5.93 (1H, ddt, J ¼ 16.6, 10.4, 6.4 Hz, CH]CH2),
5.11–5.03 (2H, m, CH]CH2), 3.34 (2H, d, J ¼ 6.6 Hz, CH2).
3-Allyliodobenzene (9e). The general procedure was
employed for the allylation of 3-iodophenylboronic acid MIDA
ester (36 mg, 0.10 mmol). Yield determined by 1H NMR: 91%.
Analytical data were in accordance with literature values.16 1H
NMR (400 MHz, CDCl3) d 7.57–7.53 (2H, m, Ar-H), 7.17–7.14
(1H, m, Ar-H), 7.06–7.00 (1H, m, Ar-H), 5.92 (1H, ddt, J ¼ 18.0,
10.7, 6.7 Hz, CH]CH2), 5.13–5.06 (2H, m, CH]CH2), 3.33 (2H,
d, J ¼ 6.6 Hz, CH2).
3-Allylnitrobenzene (9f). The general procedure was
employed for the allylation of 3-nitrophenylboronic acid MIDA
ester (83 mg, 0.30 mmol). Yield determined by 1H NMR: 92%.
Analytical data were in accordance with literature values.17 1H
NMR (400 MHz, CDCl3) d 8.08–8.06 (2H, m, Ar-H), 7.54–7.51
(1H, m, Ar-H), 7.46 (1H, ddd, J¼ 7.6, 7.0, 1.6 Hz, Ar-H), 5.96 (1H,
ddt, J ¼ 16.8, 10.1, 6.7 Hz, CH]CH2), 5.17 (1H, dq, J ¼ 10.3,
1.4 Hz, CH]CHa), 5.13 (1H, dq, J ¼ 17.3, 1.6 Hz, CH]CHb),
3.50 (2H, d, J ¼ 6.6 Hz, CH2).
2-Allylcyanobenzene (9g). The general procedure was
employed for the allylation of 2-cyanophenylboronic acid MIDA
ester (77 mg, 0.30 mmol). Yield determined by 1H NMR: 88%.
Analytical data were in accordance with literature values.18 1H
NMR (400 MHz, CDCl3) d 7.63 (1H, dd, J ¼ 7.7, 1.1 Hz, Ar-H),
7.53 (1H, td, J ¼ 3.9, 1.4 Hz, Ar-H), 7.36–7.28 (2H, m, Ar-H),
5.95 (1H, ddt, J ¼ 16.9, 10.2, 6.6 Hz, CH]CH2), 5.17–5.08 (2H,
m, CH]CH2), 3.61 (2H, d, J ¼ 6.6 Hz, CH2).
2-Phenyl-1,4-pentadiene (9h). The general procedure was
employed for the allylation of 1-phenylvinylboronic acid MIDA
ester (78 mg, 0.30 mmol). Yield determined by 1H NMR: 89%.
Analytical data were in accordance with literature values.19 1H
NMR (400 MHz, CDCl3) d 7.47–7.42 (2H, m, Ar-H), 7.36–7.30
(2H, m, Ar-H), 7.30–7.25 (1H, m, Ar-H), 5.91 (1H, ddt, J ¼ 17.1,
10.1, 6.6 Hz, CH]CH2), 5.42–5.41 (1H, m, C]CHa), 5.16–5.04
(3H, m, C]CHb, CH]CH2), 3.27–3.25 (2H, m, CH2).RSC Adv., 2020, 10, 30624–30630 | 30627
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View Article Online4-Allylphenol (9i). The general procedure was employed for
the allylation of 4-hydroxyphenylboronic acid MIDA ester
(31 mg, 0.10 mmol), except that K3PO4 (aq.) was replaced with
3 M aq. NaHCO3. Yield determined by
1H NMR: 28%. Analytical
data were in accordance with literature values.20 1H NMR (400
MHz, CDCl3) d 7.06 (2H, d, J ¼ 8.4 Hz, Ar-H), 6.78 (2H, d, J ¼
8.5 Hz, Ar-H), 5.95 (1H, ddt, J ¼ 16.7, 10.4, 6.7 Hz, CH]CH2),
5.08–5.03 (2H, m, CH]CH2), 4.86 (1H, s, OH), 3.32 (2H, d, J ¼
6.7 Hz, CH2).
2-Allylfuran (9j). The general procedure was employed for the
allylation of 2-furanylboronic acid MIDA ester (22 mg, 0.10
mmol), except that the reaction was run at room temperature.
Yield determined by 1H NMR: 45%. Analytical data were in
accordance with literature values.21 1H NMR (400 MHz, CDCl3)
d 7.41 (1H, d, J ¼ 2.4 Hz, Ar-H), 7.32 (1H, d, J ¼ 2.8 Hz, Ar-H),
6.29 (1H, d, J ¼ 2.8 Hz, Ar-H), 6.02 (1H, d, J ¼ 3.1 Hz, Ar-H),
5.97–5.88 (1H, m, CH]CH2), 5.16–5.10 (2H, m, CH]CH2),
3.39 (2H, d, J ¼ 6.5 Hz, CH2).
2-Allyl-N-Boc pyrrole (9k). The general procedure was
employed for the allylation of N-Boc-pyrrole-2-boronic acid
MIDA ester (32 mg, 0.10 mmol). Yield determined by 1H NMR:
67%. Analytical data were in accordance with literature values.22
1H NMR (400 MHz, CDCl3) d 7.22 (1H, dd, J ¼ 1.8, 1.5 Hz, Ar-H),
6.09 (1H, t, J¼ 3.3 Hz, Ar-H), 6.02 (1H, ddt, J¼ 16.7, 10.2, 6.4 Hz,
CH]CH2), 5.98–5.96 (1H, m, Ar-H), 5.10–5.02 (2H, m, CH]
CH2), 3.61 (2H, dd, J ¼ 6.3, 1.2 Hz, CH2), 1.58 (9H, s, C(CH3)3).
(E)-1-Phenyl-5,5-dimethylhexene (9l). A 4 mL screw-top glass
vial was charged with neopentyl boronic acid MIDA ester
(45 mg, 0.20 mmol), benzene (1.25 mL), cinnamyl chloride
(0.030 mL, 0.30 mmol) and Pd2dba3 (10 mg, 0.011 mmol) and
was stirred vigorously. A 3 M aq. solution of K3PO4 (0.5 mL) was
added and the vial was sealed under ambient atmosphere. The
resulting mixture was heated to 60 C by immersion of the
entire vial into a preheated aluminium block until the substrate
had been consumed, as judged by TLC analysis. The reaction
mixture was cooled to room temperature, quenched with 1 M
aq. NaOH (10 mL) then extracted with Et2O (3  10 mL). The
combined organic extracts were dried (Na2SO4), ltered and
concentrated carefully in vacuo. Addition of 1,3,5-trimethox-
ybenzene (17mg, 0.10mmol) allowed determination of the yield
by 1H NMR: 58% 1H NMR (400 MHz, CDCl3) d 7.37–7.27 (m, 4H,
Ar-H), 7.23–7.17 (m, 1H, Ar-H), 6.40 (d, J ¼ 15.8 Hz, 1H, CH-Ph),
6.25 (dt, J ¼ 15.8, 6.6 Hz, 1H, CH–CH2), 2.25–2.16 (m, 2H, CH2),
1.42–1.34 (m, 2H, CH2), 0.95 (s, 9H, 3 CH3); 13C NMR (100
MHz, CDCl3) d 138.1 (C), 132.0 (CH), 129.4 (CH), 128.6 (2 CH),
126.8 (2 CH), 126.0 (CH), 43.8 (CH2), 30.6 (C), 29.5 (3 CH3),
28.6 (CH2); HRMS (EI) exact mass calculated for C14H20 [M]
+m/z
188.1565, found m/z 188.1557.
L-Phenylalanine-N-[(1,1-dimethylethoxy)carbonyl]-4-[(2E)-3-
phenyl-2-propen-1-yl]-, methyl ester (9m). The general proce-
dure was employed for the allylation of boronic MIDA ester
(43 mg, 0.10 mmol) using cinnamyl chloride (0.030 mL, 0.20
mmol) except for that dioxane was changed for 1.25 mL of
benzene. Purication by silica chromatography using 4% ethyl
acetate in petroleum ether afforded the title compound as
a colourless oil (39 mg, 99%). Analytical data were in accordance30628 | RSC Adv., 2020, 10, 30624–30630with literature values.23 1H NMR (400 MHz, CDCl3) d 7.38–7.33
(m, 2H, Ar-H), 7.32–7.27 (m, 2H, Ar-H), 7.23–7.15 (m, 3H, Ar-H),
7.09–7.03 (m, 2H, Ar-H), 6.45 (d, J ¼ 15.8 Hz, 1H, CH2CH]CH),
6.33 (dt, J ¼ 15.8, 6.7 Hz, 1H, CH2CH]CH), 4.96 (d, J ¼ 8.4 Hz,
1H, NH), 4.58 (q, J¼ 6.8 Hz, 1H, CH), 3.72 (s, 3H, OCH3), 3.52 (d,
J ¼ 6.8 Hz, 2H, CH2), 3.06 (m, 2H, CH2), 1.41 (s, 9H, 3 CCH3).
13C NMR (101 MHz, CDCl3) d 172.5 (C), 155.2 (C), 139.1 (C),
137.6 (C), 133.9 (C), 131.3 (CH), 129.6 (2 CH), 129.2 (CH), 129.0
(2 CH), 128.6 (2 CH), 127.3 (CH), 126.3 (2 CH), 80.1 (C),
54.6 (CH), 52.3 (CH3), 39.1 (CH2), 38.1 (CH2), 28.5 (3 CH3). IR
(thin lm): 1719, 1366, 1165, 692 cm1. HRMS (ESI) exact mass
calculated for C24H29NO4Na [M + Na]
+ m/z 418.1989, found m/z
418.1979.
2-(2-Methyl-2-propen-1-yl)-naphthalene (11a). The general
procedure was employed for the allylation of 2-naphthylboronic
acid MIDA ester (85 mg, 0.30 mmol) using 2-methylallyl
bromide (0.030 mL, 0.30 mmol). Purication by ash chroma-
tography (petroleum ether) afforded the title compound as
a colourless oil (47.2 mg, 86%). Analytical data were in accor-
dance with literature values.24 1H NMR (500 MHz, CDCl3)
d (ppm): 7.83–7.78 (3H, m, Ar-H), 7.65 (1H, s, Ar-H), 7.45 (2H,
quintet d, J ¼ 6.8, 1.5 Hz, Ar-H), 7.35 (1H, dd, J ¼ 8.4, 1.7 Hz, Ar-
H), 4.88–4.87 (1H, m, C]CHa), 4.81–4.80 (1H, m, C]CHb), 3.50
(2H, s, CH2), 1.72 (3H, s, CH3).
2-(3-Phenyl-2-propen-1-yl)-naphthalene (11b). The general
procedure was employed for the allylation of 2-naphthylboronic
acid MIDA ester (32 mg, 0.10 mmol) using cinnamyl chloride
(0.030 mL, 0.20 mmol). Purication by ash chromatography
(petroleum ether) afforded the title compound as a colourless
oil (20.2 mg, 83%). Analytical data were in accordance with
literature values.25 1H NMR (400 MHz, CDCl3) d 7.85–7.80 (3H,
m, Ar-H), 7.70 (1H, s, Ar-H), 7.50–7.43 (2H, m, Ar-H), 7.41–7.38
(3H, m, Ar-H), 7.34–7.29 (2H, m, Ar-H), 7.25–7.21 (1H, m, Ar-H),
6.53 (1H, d, J ¼ 15.8 Hz, CH2CH]CH), 6.45 (1H, dt, J ¼ 15.8,
6.3 Hz, CH2CH]CH), 3.73 (2H, d, J ¼ 6.2 Hz, CH2CH]CH).
2-(2-Buten-1-yl)-naphthalene/2-(1-methyl-2-propen-1-yl)-
naphthalene ((major) 11c/11c* (minor)). The general procedure
was employed for the allylation of 2-naphthylboronic acid MIDA
ester (32 mg, 0.10 mmol) using 3-chlorobut-1-ene (0.020 mL,
0.20 mmol). Purication by ash chromatography (petroleum
ether) afforded the title compounds as a colourless oil (12.4 mg,
68%, 1.6 : 1). Analytical data were in accordance with literature
values.24 1H NMR (400 MHz, CDCl3) d 7.82–7.77 (3H, m, Ar-H),
7.66 (1H, s, Ar-H), 7.62 (1H, s, Ar-H), 7.48–7.40 (2H, m, Ar-H),
7.39–7.32 (1H, m, Ar-H), 6.10 (1H, ddd, J ¼ 16.9, 10.3, 6.4 Hz,
CH]CH2), 5.72–5.54 (2H, m, CH]CH), 5.14–5.08 (2H, m, CH]
CH2), 3.67–3.57 (1H, m, CHCH3), 3.49 (2H, dd, J ¼ 6.5, 1.2 Hz,
CH2), 1.73 (3H, dq, J ¼ 6.1, 1.4 Hz, CHCH3), 1.47 (3H, d, J ¼
7.0 Hz, CH]CHCH3).
2-(3-Methyl-2-buten-1-yl)-naphthalene/2-(2-methyl-3-buten-
2-yl)-naphthalene ((major) 11d/11d* (minor)). The general
procedure was employed for the allylation of 2-naphthylboronic
acid MIDA ester (32 mg, 0.10 mmol) using prenyl chloride
(0.020 mL, 0.20 mmol). Purication by ash chromatography
(petroleum ether) afforded the title compounds as a colourless
oil (15.1 mg, 77%, 3 : 1). Analytical data were in accordance with
literature values.26 1H NMR (400 MHz, CDCl3) d 0.82 (3H, m, Ar-This journal is © The Royal Society of Chemistry 2020
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View Article OnlineH), 7.62 (1H, s, Ar-H), 7.52–7.40 (2H, m, Ar-H), 7.34 (1H, dd, J ¼
8.5, 1.8 Hz, Ar-H), 6.12 (1H, dd, J ¼ 17.3, 10.7 Hz, CH]CH2),
5.43 (1H, septet, J ¼ 7.3, 1.4 Hz, CH]C(CH3)2), 5.15–5.10 (2H,
m, CH]CH2), 3.52 (2H, d, J¼ 7.3 Hz, CH2), 1.79 (6H, dd, J¼ 4.4,
1.4 Hz, CH]C(CH3)2), 1.52 (6H, s, 2 CH3).
2-(2-Propen-1-yl-3,3-d2)-naphthalene/2-(2-propen-1-yl-1,1-
d2)-naphthalene (13/14). The general procedure was employed
for the allylation of 2-naphthylboronic acid MIDA ester (28 mg,
0.10 mmol) except that Pd2dba3 was replaced by Pd(OAc)2
(5 mol%). Coupling with freshly prepared dideuteroallyl
bromide27 (0.23 mL, 0.89 M in Et2O, 0.20 mmol) was followed by
purication by ash chromatography (petroleum ether) to
afford the title compounds as a colourless oil (14.1 mg, 83%,
1 : 1 isomer ratio). Analytical data were in accordance with
literature values.28 1H NMR (400 MHz, CDCl3) d 7.83–7.78 (3H,
m, Ar-H), 7.64 (1H, dd, J ¼ 1.8, 0.8 Hz, Ar-H), 7.49–7.42 (2H, m,
Ar-H), 7.35 (1H, dd, J ¼ 8.4, 1.8 Hz, Ar-H), 6.09–6.02 (1H, m,
CH]CH2/CH]CD2), 5.16 (0.5H, dd, J ¼ 12.0, 2.0 Hz, CH]
CHH), 5.13 (0.5H, dd, J¼ 5.2, 2.0 Hz, CH]CHH), 3.57 (1H, dd, J
¼ 6.6, 0.7 Hz, CH2CH]CD2); 13C NMR (100MHz, CDCl3) d 137.7
(2 C), 137.4 (CH), 137.2 (CH), 133.8 (2 C), 132.3 (2 C), 128.0
(2 CH), 127.8 (2 CH), 127.6 (2 CH), 127.5 (2 CH), 126.8
(2 CH), 126.1 (2 CH), 125.4 (2 CH), 116.2 (CH2), 115.7 (p,
1J(C-D) ¼ 23.7 Hz, CD2), 40.4 (CH2), 39.8 (p, 1J(C-D) ¼ 19.6 Hz,
CD2); IR (thin lm) 3053, 2923, 2113, 1689 cm
1; HRMS (EI)
exact mass calculated for C13H10D2 [M]
+ m/z 170.1059, found m/
z 170.1080.
tert-Butyl 2-(4-phenyl boronic acid MIDA ester)-propionate
(16). Following a literature procedure,11 to a dry 2-necked ask
with a condenser was added zinc powder (1.2 g, 19 mmol), THF
(7.5 mL) and trimethylsilyl chloride (0.080 mL, 0.63 mmol). The
mixture was stirred for 15 minutes. A solution of tert-butyl 2-
bromopropionate (2.10 mL, 12.5 mmol) in THF (17.5 mL) was
added over 2–3 minutes with an exotherm observed. Once the
mixture returned to room temperature, stirring was dis-
continued. The solution was used directly in the next step
(assumed concentration: 0.23 M). To a dry ask charged with
a stir bar, was added 4-bromophenylboronic acid MIDA ester
(0.31 g, 1.0 mmol), Pd(dba)2 (5.8 mg, 0.010 mmol), QPhos
(7.1 mg, 0.010 mmol) and THF (3.0 mL). The mixture was stirred
briey, then a freshly prepared solution of tert-butyl 2-bromo-
zincpropionate in THF (8.7 mL, 2.0 mmol) was added. The
reaction mixture was stirred at 65 C for 1.5 h. Aer cooling to
room temperature, the reaction was quenched with sat. aq.
NH4Cl (10 mL), followed by addition of brine (10 mL). The
phases were separated, and the organic phase was dried
(Na2SO4), ltered and concentrated in vacuo. The residue was
adsorbed onto silica gel then purication by ash chromatog-
raphy (diethyl ether : methanol, 98.5 : 1.5 then THF) afforded
the title compound as a light pink solid (0.32 g, 90%).1H NMR
(400 MHz, d6-DMSO) d 7.39 (2H, d, J¼ 8.1 Hz, Ar-H), 7.25 (2H, d,
J ¼ 8.1 Hz, Ar-H), 4.32 (2H, d, J ¼ 17.2 Hz, 2 NCHH), 4.11 (2H,
d, J ¼ 17.2 Hz, 2 NCHH), 3.64 (1H, q, J ¼ 7.1 Hz, CHCH3), 2.49
(3H, s, NCH3), 1.40 (3H, s, CH3), 1.34 (9H, s, 3 CH3); 13C NMR
(100 MHz, d6-DMSO) d 174.3 (C), 173.0 (C), 169.3 (2 C), 141.6
(C), 132.5 (2 CH), 126.5 (2 CH), 79.9 (C), 61.8 (CH2), 47.5
(CH3), 45.5 (CH), 27.6 (3 CH3), 18.5 (CH3); IR (solid) 2978,This journal is © The Royal Society of Chemistry 20201724, 1713, 1367, 1150 cm1; HRMS (ESI) exact mass calculated
for C18H24BNNaO6 [M + Na]
+ m/z 384.1589, found m/z 384.1575.
tert-Butyl 2-(4-methallylphenyl)-propionate (17). The general
procedure was employed for the allylation of tert-butyl MIDA
(36 mg, 0.10 mmol) using 2-methylallyl bromide (0.020 mL, 0.20
mmol). Yield was determined by 1H NMR: 73%. 1H NMR (400
MHz, CDCl3) d 7.21 (2H, d, J ¼ 8.1 Hz, Ar-H), 7.13 (2H, d, J ¼
8.1 Hz, Ar-H), 4.81–4.79 (1H, m, C]CHH), 4.73–4.71 (1H, m,
C]CHH), 3.59 (1H, q, J ¼ 7.2 Hz, CHCH3), 3.29 (2H, s, Ar-
CH2C), 1.67 (3H, s, CCH3), 1.44 (3H, d, J ¼ 7.2 Hz, CHCH3), 1.39
(9H, s, 3 CCH3); 13C NMR (100 MHz, CDCl3) d 173.9 (C), 145.2
(C), 139.0 (C), 138.3 (C), 128.9 (2 CH), 127.3 (2 CH), 111.6
(CH2), 80.3 (C), 46.0 (CH), 44.1 (CH2), 27.8 (3 CH3), 21.9 (CH3),
18.3 (CH3); IR (thin lm) 2978, 2934, 1728, 1452, 1148,
739 cm1; HRMS (ESI) exact mass calculated for C17H24NaO2 [M
+ Na]+ m/z 283.1669, found m/z 283.1666.
Ibuprofen (18). A stirred solution of ester (18 mg, 0.069
mmol), palladium acetate (1.1 mg, 0.0050 mmol) and DavePhos
(3.9 mg, 0.010 mmol) in dioxane/H2O (1.25 mL/0.25 mL) under
an argon atmosphere was evacuated and backlled with H2. The
reaction mixture was stirred at room temperature under a H2
atmosphere for 16 h. The ask was evacuated and backlled
with argon, then conc. HCl (0.60 mL) was added to give an
overall concentration of 4 M HCl. The reaction mixture was
stirred at room temperature for 16 h then quenched with 2 M
aq. NaOH. The mixture was extracted with Et2O (2  10 mL)
then the aqueous phase adjusted to pH 1 with 2 M aq. HCl. The
aqueous phase was extracted with Et2O (2  10 mL) then the
combined organic extracts were dried (Na2SO4), ltered and
concentrated in vacuo affording the title compound as a white
solid (9.5 mg, 67%). Analytical data were in accordance with
literature values.29 1H NMR (400 MHz, CDCl3) d 8.62 (1H, s,
COOH), 7.22 (2H, d, J¼ 7.9 Hz, Ar-H), 7.10 (2H, d, J¼ 7.8 Hz, Ar-
H), 3.71 (1H, q, J¼ 7.1 Hz, CHCH3), 2.44 (2H, d, J¼ 7.2 Hz, CH2),
1.84 (1H, septet, J ¼ 6.6 Hz, CH(CH3)2), 1.50 (3H, d, J ¼ 7.1 Hz,
CHCH3), 0.90 (6H, d, J ¼ 6.6 Hz, CH(CH3)2).
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